However, the association between certain bDMARD with urinary tract cancer still needs further investigation, as a recent report from the anti-Rheumatic Treatment in Sweden Register(ARTIS) group reported a statistically significantly increased risk of urinary tract cancer with Tumor necrosis factor inhibitors (TNFi), rituximab(RTX) as well as abatacept(ABA) when comparing site-specific relative risks for cancer with b/tsDMARDs vs. b/tsDMARD naïve RA (74). This evidence concerns the gene TNF and cancer.